Navigating the highs and lows of psychedelic therapies : vim

Regulators face new challenges over whether — and how — to allow people to receive mind-altering drugs to treat mental health conditions.

Related Keywords

Portugal , Jamaica , United States , Netherlands , Spain , London , City Of , United Kingdom , America , Dutch , Cole Burston , Brent Lewin Getty , James Rucker , Myles Katz , George Goldsmith , Michael Pollan , Kirk Rutter , Synthesis Institute , Researchers At Kings College London , Netflix , South America , Kings College London , Wild West , Chemicals , Clinical Trials , Data , Doctors , Drug And Device Safety , England , Governance , Health Systems , History , Industry , Major And Chronic Diseases , Medicines , Mental Health , Patients , Pharma , Policy , Psychedelics , Regulation , Regulatory , Research , Research And Development , Rights , Risk And Compliance , Safety , Society And Culture , The Netherlands , Transparency ,